Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Acetyl-CoA synthetase 2–Transcription factor EB (ACSS2–TFEB) metabolic axis is a critical regulatory pathway that links cellular metabolism to epigenetic control and autophagy (Li et al., Nature, 2017; Yin et al., Cell Death & Disease, 2025). Acetyl-CoA synthetase 2 (ACSS2) is an enzyme that converts acetate into acetyl-CoA, and under conditions of metabolic stress or hypoxia, it translocates to the nucleus (Li et al., Nature, 2017; NIH, 2022). In the nucleus, ACSS2 forms a complex with Transcription Factor EB (TFEB), the master regulator of the autophagy-lysosome pathway, and provides a local supply of acetyl-CoA for histone acetylation at the promoters of TFEB target genes (Li et al., Nature, 2017; Yin et al., Cell Death & Disease, 2025). This axis is frequently hijacked by cancer cells, such as those in glioblastoma and breast cancer, to survive in nutrient-poor microenvironments by maintaining autophagic flux (NIH, 2022; Miller et al., 2021). Targeting this axis, primarily through ACSS2 inhibitors like MTB-9655, offers a strategy to disrupt cancer cell energy homeostasis and sensitize tumors to other therapies (ASCO, 2022; NCI, 2022). Beyond oncology, the axis is also implicated in neurodegenerative and metabolic diseases where autophagy and lipid metabolism are dysregulated (NIH, 2025; Yin et al., Cell Death & Disease, 2025). Potential safety concerns include the disruption of basal autophagy in normal tissues and organ-specific metabolic dysregulation, although ACSS2 inhibition has shown a favorable safety profile in early clinical studies (ASCO, 2022; NIH, 2025).
Inhibition of ACSS2-mediated nuclear acetyl-CoA production, which reduces histone acetylation at TFEB-target gene promoters, thereby suppressing the expression of autophagy and lysosomal genes and inducing metabolic stress in cancer cells.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Acetyl-CoA synthetase 2 (ACSS2)–Transcription factor EB (TFEB) metabolic axis (ACSS2–TFEB axis).